Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

Antoni, Sébastien; Ferlay, Jacques; Soerjomataram, Isabelle; Znaor, Ariana; Jemal, Ahmedin; Bray, Freddie

doi:10.1016/j.eururo.2016.06.010

Cited by 2,078 publications

(1,627 citation statements)

References 44 publications

Supporting

Mentioning

1,570

Contrasting

Unclassified

Order By: Relevance

“…Bladder cancer is one of the most common malignant tumors that affects the urinary system and its incidence and mortality rate is increasing (3). Bladder cancer typically exhibits atypical clinical symptoms, lacks specificity and is not easily diagnosed in the early stages (2). The majority of patients are identified to have bladder cancer during the treatment of other diseases, and have therefore missed the opportunity for optimal treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C

Ping

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…According to statistics published in 2012, the number of new bladder cancer cases in the world reached 430,000, and the number of mortalities caused by bladder cancer reached 165,000 (2). Bladder cancer is one of the most common malignant tumors that affects the urinary system and its incidence and mortality rate is increasing (3).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C

Ping

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Bladder cancer is the ninth most frequent neoplasia worldwide [1], with 70% of new cases being non-invasive [2]. Several studies have shown that the risk of progression and recurrence of non-invasive bladder neoplasia with bacillus CalmetteGuerin (BCG) is lower than with other intravesical chemotherapies such as mitomycin, epirubicin and gemcitabine [3,4].…”

Section: Introductionmentioning

confidence: 99%

Tuberculosis Miliary in Patients Treated With Bacillus Calmette-Guerin Immunotherapy: Case Report

et al. 2017

View full text Add to dashboard Cite

Bacillus Calmette-Guerin (BCG), a live attenuated form of Mycobacterium bovis (M. bovis), is the most effective intravesical agent in the treatment of non-invasive bladder cancer. This therapy can cause minor complications like urinary frequency, fever, dysuria and hematuria, but it can also cause more serious systemic complications such as hepatitis, pneumonitis and sepsis. Miliary tuberculosis is a very rare complication of BCG immunotherapy and is associated to high mortality, thus this diagnosis must be early considered and early treatment should be implemented. The authors report a case of miliary tuberculosis after treatment with intravesical BCG, with isolation of M. bovis. The patient presented clinical and imaging improvement after initiation of tuberculostatic agents.

show abstract

“…[1] According to the GLOBOCAN, the highest incidence rates were observed in men in Southern and Western Europe, North America, as well as certain countries in Northern Africa and Western Asia. [2] Turkey is one of the five countries with the highest age-standardized incidence (16.6/100.000) as well as the highest age-standardized death rate (6.6/100.000). [3] According to the data by Turkish Ministry of Health, Department of Fight Against Cancer, BC is the 3 rd frequent cancer type after lung and prostate cancers in men.…”

Section: Introductionmentioning

confidence: 99%

The association between variant urothelial histologies, pathological stage and disease specific survival in patients with bladder cancer

Böyük

Şanlı

Erdem

et al. 2018

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: We aimed to compare the oncological outcomes of patients with variant urothelial histologies (VH) with pure urothelial histology (PUH) in bladder cancer (BC) patients. Material and methods:This study includes 223 patients who underwent radical cystectomies (RCs) between September 2006 and July 2016 with complete follow-up data A retrospective screening was performed to identify the patients with PUH and VH. The primary outcomes of interest were pathological stage of disease at RC and disease-specific survival (DSS). For comparison of categorical variables, Fisher's exact test and Pearson chi-square and for continuous variables Wilcoxon rank-sum and Mann-Whitney U tests were used. Kaplan-Meier (KM) method was used for survival analysis and log-rank test was used for comparison of survival rates. Predictors of survival were detected with mulitivariable Cox-proportional hazards model including the variables such as gender, age, existence of VH, lymph node dissection (LND) type and pathological stage of the disease. Results:A moderate-degree correlation was detected between VH and pathological stages of RC (r= 0.45, p<0.001). In PUH group, 39 (25.8%) of 151 patients died after a median follow-up of 20 (0-107) months; whereas 37 (51.4%) of 72 patients with VH died after a median follow-up of 16.5 (0-104) months (p<0.001). In terms of pathological stage, the number of patients with PUH and VH were at stages pT0-2 (n=100; 66.2% vs. n=19; 26.4%), pT3-4 (n=35; 23.2% vs. 38; 52.8%, and in 16 (10.6%) and 15 (20.8%) patients with LN positivity, respectively (p<0.001). KM survival analysis revealed a significantly decreased DSS in patients with VH compared to PUH (p<0.001). Meanwhile, pathological disease stage and existence of VH were found to be associated with decreased DSS in the multivariate model. Conclusion:The present study revealed that VH is associated with advanced pathological tumor stage at RC and decreased DSS compared to patients with PUH in patients with BC.

show abstract

Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

Cited by 2,078 publications

References 44 publications

MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C

MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C

Tuberculosis Miliary in Patients Treated With Bacillus Calmette-Guerin Immunotherapy: Case Report

The association between variant urothelial histologies, pathological stage and disease specific survival in patients with bladder cancer

Contact Info

Product

Resources

About